{
    "abstract": "The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.",
    "author": "Ariel R. Weisman; Justin Kim; Roseline Agyekum; Oliva Kuthuru; Leticia Kuri-Cervantes; Aaron M. Rosenfeld; Luanne Bershaw; Ajinkya Pattekar; Eline T. Luning Prak; Allison R. Greenplate; M. Betina Pampena; Sigrid Gouma; Elizabeth M. Anderson; Claudia P. Arevalo; Marcus J. Bolton; Nicholas Han; Nuala J. Meyer; Eileen C. Goodwin; Amy E. Baxter; Caroline A.G. Ittner; Sokratis Apostolidis; Madison E. Weirick; Nilam S. Mangalmurti; Tiffanie K. Jones; Laura Vella; Jeannete Dougherty; Scott E. Hensley; Michael R. Betts; Wenzhao Meng; Divij Mathew; E. John Wherry",
    "date": 2020,
    "doi": "10.1101/2020.05.18.101717",
    "identifiers": {
        "url": "http://biorxiv.org/cgi/content/short/2020.05.18.101717"
    },
    "title": "Immunologic perturbations in severe COVID-19/SARS-CoV-2 infection",
    "funding": [
        {
            "award-group": [
                {
                    "funding-source": "Janssen Pharmaceuticals,"
                },
                {
                    "funding-source": "Roche Diagnostics Corporation"
                }
            ],
            "funding-statement": "ETLP is currently receiving funding from Janssen Pharmaceuticals, and is part of a scientific advisory panel for Roche Diagnostics Corporation for work unrelated to this publication"
        }
    ]
}